Clinical Trial Update: Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY) [Phase 1, Phase 2]

View source ↗

Summary

Phase I/IIa dose-finding study evaluating a triplet regimen of relatlimab, ipilimumab, and nivolumab as first-line therapy for metastatic melanoma; status is no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Relatlimab (relatlimab)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Melanoma | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING